Elevation of serum pyruvate kinase M2 (PKM2) in IBD and its relationship to IBD indices.

Journal: Clinical biochemistry
PMID: 29273328

Abstract

OBJECTIVES: Endoscopy remains the gold standard to diagnose and evaluate inflammatory bowel disease (IBD) activity. Current biomarkers or their combinations cannot adequately predict IBD risk, diagnosis, progression or relapse, and response to therapy. Pyruvate kinase M2 (PKM2) is emerging as a significant mediator of the inflammatory process. We aimed to assess levels of serum PKM2 in healthy and newly diagnosed IBD patients and its relationship with IBD indices and microbiota changes.

Authors

  • Ahmed A Almousa
    Drug Discovery and Development Research Group, College of Pharmacy and Nutrition, University of Saskatchewan, 107 Wiggins Road, Saskatoon, Saskatchewan, Canada.
  • Marc Morris
    Drug Discovery and Development Research Group, College of Pharmacy and Nutrition, University of Saskatchewan, 107 Wiggins Road, Saskatoon, Saskatchewan, Canada.
  • Sharyle Fowler
    Department of Gastroenterology, College of Medicine, University of Saskatchewan, Saskatoon, Canada.
  • Jennifer Jones
    Division of Digestive Care & Endoscopy, Department of Community Health and Epidemiology, Dalhousie University, Halifax, Canada.
  • Jane Alcorn
    Drug Discovery and Development Research Group, College of Pharmacy and Nutrition, University of Saskatchewan, 107 Wiggins Road, Saskatoon, Saskatchewan, Canada. Electronic address: jane.alcorn@usask.ca.

Keywords

External Resources

Popular Topics
Recent Journals